Search Results

You are looking at 81 - 90 of 1,580 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Matteo Lambertini, Marcello Ceppi, Richard A. Anderson, David A. Cameron, Marco Bruzzone, Maria Alice Franzoi, Claudia Massarotti, Sarra El-Abed, Yingbo Wang, Christophe Lecocq, Paolo Nuciforo, Rebecca Rolyance, Lajos Pusztai, Joohyuk Sohn, Maria Maddalena Latocca, Luca Arecco, Barbara Pistilli, Kathryn J. Ruddy, Alberto Ballestrero, Lucia Del Mastro, Fedro A. Peccatori, Ann H. Partridge, Cristina Saura, Michael Untch, Martine Piccart, Serena Di Cosimo, Evandro de Azambuja, and Isabelle Demeestere

Tumor Characteristics AMH values differed significantly at the 3 time points ( P <.001; Figure 2A ). At screening/baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56–2.62 ng/mL). After 2 weeks of anti-HER2 treatment alone, a small reduction in

Full access

Role of Immunotherapy for Renal Cell Cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim

in search of biomarker of response to IL-2 that can be validated in subsequent studies. Table 1 Response by Baseline Characteristics The therapeutic armamentarium for metastatic RCC considerably expanded in the past several years with

Full access

Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?

Jia-Wei Lv, Yu-Pei Chen, Guan-Qun Zhou, Xu Liu, Ying Guo, Yan-Ping Mao, Jun Ma, and Ying Sun

subsequent publications, and to identify the trends of reporting quality and associated characteristics. Methods Data Source and Study Sample Data were obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting data

Full access

Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

nonmetastatic ACC using a large population-based database. In addition, we sought to identify a subset of patients with ACC who may be more likely to benefit from adjuvant radiation based on their tumor characteristics. Patients and Methods Study

Full access

CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study

Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, and Kumar Alagapan

Incidental pulmonary embolisms (IPE) are commonly discovered in cancer patients during their cancer staging and surveillance imaging studies. Examining the clinical characteristics and outcomes of these incidents in cancer patients may guide the

Full access

CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer

Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem

240 (46.0%) were HER2-low, 142 (27.2%) HER2+, 46 (8.8%) HER2 IHC 0, and 94 (18.0%) had unknown/incomplete HER2 results. Among the HER2-low patients, 198 (82.5%) were HR+, 40 (16.7%) were HR-, and 2 (0.8%) were unknown. The tumor characteristics and

Full access

Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations

Sheena Bhalla, Vijaya Natchimuthu, Jessica L. Lee, Urooj Wahid, Hong Zhu, Noel O. Santini, Travis Browning, Heidi A. Hamann, David H. Johnson, Hsienchang Chiu, Simon J. Craddock Lee, and David E. Gerber

. Demographic characteristics were collected from the EHR and/or patient report at baseline. Comorbidities were categorized using the Charlson comorbidity index. 23 Performance of LDCT, Lung-RADS results, and other steps in the LCS process were captured through

Full access

Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

classified according to the IIQ-7 score as major (33–99), moderate (5–29), or no impact (0). Statistical Analyses For this exploratory study, statistical significance ( P <.05) was unadjusted for multiple hypothesis testing. Demographic characteristics (age

Full access

CLO20-058: Characteristics of Gynecological Anamnesis and its Prognostic Role in Azerbaijani Women With Breast Cancer

Sevinj E. Rahimzade, Jamil A. Aliyev, Elkhan E. Kazimov, Leylakhanum A. Melikova, Konul S. Mardanova, Turkan E. Mansurova, and Elchin B. Mansurov

gynecological anamnesis characteristics in Azerbaijani women with BC and investigation of the prognostic significance of the relationship with the stage (S) of BC and biological subtypes (BS). Materials: 570 randomly selected women with BC were included in the